CY1106530T1 - Ανταγωνιστες vegf για τη θεραπευτικη αγωγη διαβητη - Google Patents

Ανταγωνιστες vegf για τη θεραπευτικη αγωγη διαβητη

Info

Publication number
CY1106530T1
CY1106530T1 CY20071100538T CY071100538T CY1106530T1 CY 1106530 T1 CY1106530 T1 CY 1106530T1 CY 20071100538 T CY20071100538 T CY 20071100538T CY 071100538 T CY071100538 T CY 071100538T CY 1106530 T1 CY1106530 T1 CY 1106530T1
Authority
CY
Cyprus
Prior art keywords
vegf
diabetes
therapeutic treatment
vegf antagonists
mediated activity
Prior art date
Application number
CY20071100538T
Other languages
English (en)
Inventor
Mark W. Sleeman
Stanley J. Wiegand
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1106530T1 publication Critical patent/CY1106530T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Μέθοδοι θεραπευτικής αγωγής διαβήτη σε θηλαστικά, ιδίως σε ανθρώπους, αποτρέποντας ή αναστέλλοντας VEGF-μεσολαβητική δραστικότητα. Ένας προτιμητέος αναστολέας VEGF-μεσολαβητικής δραστικότητας είναι ανταγωνιστής VEGF όπως παγίδα VEGF ικανή να δεσμεύει και να αναστέλλει τον VEGF.
CY20071100538T 2003-03-28 2007-04-19 Ανταγωνιστες vegf για τη θεραπευτικη αγωγη διαβητη CY1106530T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45879003P 2003-03-28 2003-03-28
PCT/US2004/009246 WO2004087206A2 (en) 2003-03-28 2004-03-26 Methods of treating diabetes by blocking vegf-mediated activity

Publications (1)

Publication Number Publication Date
CY1106530T1 true CY1106530T1 (el) 2012-01-25

Family

ID=33131825

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100538T CY1106530T1 (el) 2003-03-28 2007-04-19 Ανταγωνιστες vegf για τη θεραπευτικη αγωγη διαβητη

Country Status (17)

Country Link
US (1) US7052691B2 (el)
EP (1) EP1608685B1 (el)
JP (2) JP4730909B2 (el)
AT (1) ATE354592T1 (el)
AU (1) AU2004226417B2 (el)
BR (1) BRPI0408749B1 (el)
CA (1) CA2519787C (el)
CY (1) CY1106530T1 (el)
DE (1) DE602004004883T2 (el)
DK (1) DK1608685T3 (el)
ES (1) ES2278333T3 (el)
HK (1) HK1080092A1 (el)
MX (1) MXPA05008972A (el)
PL (1) PL1608685T3 (el)
PT (1) PT1608685E (el)
SI (1) SI1608685T1 (el)
WO (1) WO2004087206A2 (el)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007001241A (es) 2004-07-30 2007-07-11 Regeneron Pharma Metodos para tratar diabetes tipo i mediante el bloqueo de la actividad mediada de vegf.
PT1861116E (pt) 2005-03-25 2015-11-04 Regeneron Pharma Formulações de antagonista do vegf
CN101478949A (zh) 2006-06-16 2009-07-08 瑞泽恩制药公司 适合玻璃体内施用的vegf拮抗剂的制剂
ES2345596B1 (es) * 2009-03-26 2011-07-13 Fundacion Progreso Y Salud Composicion para la prevencion o el tratamiento de la diabetes mellitus.
US20100330098A1 (en) * 2009-06-29 2010-12-30 Kuo Calvin J Methods to regulate glucose metabolism
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
AU2015208482B2 (en) 2014-01-25 2017-02-02 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3170005B1 (en) 2014-07-18 2019-04-10 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
IL290457B1 (en) 2015-12-30 2024-10-01 Kodiak Sciences Inc Antibodies and their conjugates
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
MX2020009152A (es) 2018-03-02 2020-11-09 Kodiak Sciences Inc Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9410533D0 (en) * 1994-05-26 1994-07-13 Lynxvale Ltd In situ hybridisation and immuno-Chemical localisation of a growth factor
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP4723140B2 (ja) * 1999-06-08 2011-07-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 改善された薬物動態特性を有する改変キメラポリペプチド
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases

Also Published As

Publication number Publication date
JP2006521397A (ja) 2006-09-21
EP1608685B1 (en) 2007-02-21
DE602004004883D1 (de) 2007-04-05
HK1080092A1 (en) 2006-04-21
DE602004004883T2 (de) 2007-11-15
CA2519787C (en) 2012-06-05
CA2519787A1 (en) 2004-10-14
AU2004226417B2 (en) 2009-01-22
BRPI0408749A (pt) 2006-03-28
US20040213787A1 (en) 2004-10-28
MXPA05008972A (es) 2005-11-04
PL1608685T3 (pl) 2007-07-31
ATE354592T1 (de) 2007-03-15
WO2004087206A2 (en) 2004-10-14
JP4730909B2 (ja) 2011-07-20
US7052691B2 (en) 2006-05-30
ES2278333T3 (es) 2007-08-01
EP1608685A2 (en) 2005-12-28
PT1608685E (pt) 2007-05-31
DK1608685T3 (da) 2007-06-11
SI1608685T1 (sl) 2007-08-31
WO2004087206A3 (en) 2004-12-16
BRPI0408749B1 (pt) 2016-10-04
AU2004226417A1 (en) 2004-10-14
JP2011037894A (ja) 2011-02-24

Similar Documents

Publication Publication Date Title
CY1106530T1 (el) Ανταγωνιστες vegf για τη θεραπευτικη αγωγη διαβητη
DE60135485D1 (de) Monozyklische oder bizyklische carbozyklen und heterozyklen als hemmer von factor xa
CY2014028I1 (el) Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης
CY1109764T1 (el) Υποκατεστημενα βενζαζολια και χρηση αυτων ως αναστολεις κινασης raf
DE60325761D1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
DE60315146D1 (de) Heteroarylsubstituierte biphenylderivate als inhibitoren von p38-kinase
DE602004021838D1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
CY1108422T1 (el) Παραγωγα 4-τετραζολυλ-4φαινυλπιπεριδινης για θεραπεια πονου
NO20043442L (no) Nye substituerte benzimidazol-doseringsformer og fremgangsmater for anvendelse av samme
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1111083T1 (el) Παραγωγα νικοτιναμιδιου χρησιμα ως αναστολεις της p38
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
CY1108655T1 (el) ΘΕΙΟΖΟΛΙΔΙΝ-4-ΟΝΕΣ ΓΙΑ ΤΗΝ ΑΝΑΣΤΟΛΗ ΠΡΩΤΕΪΝΩΝ hYAK3
CY1112947T1 (el) Παραγωγα πυρρολης καταλληλα για την θεραπεια πολλαπλασιαστικων ασθενειων
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
WO2004084943A8 (en) Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
NL1025873A1 (nl) Doseringsvormen en wijzen van behandeling met vegfr-remmers.
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
ATE343582T1 (de) Derivate von (6, 7-dihydro -5h-imidazo(1,2 - a)imidazol -3 -sulfonylamino)-propionamid und deren verwendung als inhibitoren der interaktion von cams und leukointreginen
DE60214019D1 (de) Stickstoff enthaltende heterozyklen und ihre verwendung als raf inhibitoren
DK1651774T3 (da) Anvendelse af polymorfier i humant OATP-C forbundet med en virkning på statinfarmakinetik i mennesker under statinterapi
DE60227417D1 (de) Verwendung von emp9 zur prävention von proliferativen organerkrankungen
ATE409066T1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit